Cargando…

Rationale and design of the AdaptResponse trial: a prospective randomized study of cardiac resynchronization therapy with preferential adaptive left ventricular‐only pacing

The AdaptResponse trial is designed to test the hypothesis that preferential adaptive left ventricular‐only pacing with the AdaptivCRT(®) algorithm reduces the incidence of the combined endpoint of all‐cause mortality and intervention for heart failure (HF) decompensation, compared with conventional...

Descripción completa

Detalles Bibliográficos
Autores principales:	Filippatos, Gerasimos, Birnie, David, Gold, Michael R., Gerritse, Bart, Hersi, Ahmad, Jacobs, Sandra, Kusano, Kengo, Leclercq, Christophe, Mullens, Wilfried, Wilkoff, Bruce L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Ltd 2017
Materias:	Trial Design
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5606499/ https://www.ncbi.nlm.nih.gov/pubmed/28708290 http://dx.doi.org/10.1002/ejhf.895

Ejemplares similares

Differences in clinical characteristics and reported quality of life of men and women undergoing cardiac resynchronization therapy
por: Wilkoff, Bruce L., et al.
Publicado: (2020)

Rationale and design of the IRON‐CRT trial: effect of intravenous ferric carboxymaltose on reverse remodelling following cardiac resynchronization therapy
por: Martens, Pieter, et al.
Publicado: (2019)

Personalized pacing for diastolic dysfunction and heart failure with preserved ejection fraction: Design and rationale for the myPACE randomized controlled trial
por: Infeld, Margaret, et al.
Publicado: (2021)

Do Bayesian adaptive trials offer advantages for comparative effectiveness research? Protocol for the RE-ADAPT study
por: Connor, Jason T, et al.
Publicado: (2013)

Rationale and design of the randomized multicentre His Optimized Pacing Evaluated for Heart Failure (HOPE‐HF) trial
por: Keene, Daniel, et al.
Publicado: (2018)

Design of Mid‐Q Response: A prospective, randomized trial of adaptive cardiac resynchronization therapy in Asian patients
por: Kusano, Kengo, et al.
Publicado: (2022)

Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX‐AHF‐2 study
por: Teerlink, John R., et al.
Publicado: (2017)

Design and rationale of the MODULAR ATP global clinical trial: A novel intercommunicative leadless pacing system and the subcutaneous implantable cardioverter-defibrillator
por: Lloyd, Michael S., et al.
Publicado: (2023)

The PhysioVP-AF study, a randomized controlled trial to assess the clinical benefit of physiological ventricular pacing vs. managed ventricular pacing for persistent atrial fibrillation prevention in patients with prolonged atrioventricular conduction: design and rationale
por: Pastore, Gianni, et al.
Publicado: (2023)

Patiromer for the management of hyperkalaemia in patients receiving renin–angiotensin–aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial
por: Butler, Javed, et al.
Publicado: (2021)

International REgistry to assess medical Practice with lOngitudinal obseRvation for Treatment of Heart Failure (REPORT‐HF): rationale for and design of a global registry
por: Filippatos, Gerasimos, et al.
Publicado: (2015)

Rationale, challenges, and participants in a Phase II trial of a botanical product for chronic hepatitis C
por: Reddy, K Rajender, et al.
Publicado: (2012)

Rationale and Design of the Efficacy of a Standardized Diuretic Protocol in Acute Heart Failure Study
por: Dauw, Jeroen, et al.
Publicado: (2021)

Rationale and design of the SERVE-HF study: treatment of sleep-disordered breathing with predominant central sleep apnoea with adaptive servo-ventilation in patients with chronic heart failure
por: Cowie, Martin R., et al.
Publicado: (2013)

The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia) Study. Rationale and Design
por: Angus, Derek C., et al.
Publicado: (2020)

Conduction system pacing and atrioventricular node ablation in heart failure: The PACE‐FIB study design
por: Rodríguez Muñoz, Daniel, et al.
Publicado: (2023)

Statistical aspects of the TNK-S2B trial of tenecteplase versus alteplase in acute ischemic stroke: an efficient, dose-adaptive, seamless phase II/III design
por: Levin, Bruce, et al.
Publicado: (2011)

Experiences of running a stratified medicine adaptive platform trial: Challenges and lessons learned from 10 years of the FOCUS4 trial in metastatic colorectal cancer
por: Brown, Louise C, et al.
Publicado: (2022)

Rationale and design of the EMPYREAN study
por: Motoki, Hirohiko, et al.
Publicado: (2020)

Real‐world outcomes in cardiac resynchronization therapy patients: design and baseline demographics of the SMART‐ Registry
por: Gardner, Roy S., et al.
Publicado: (2021)

Rationale and design of the AUGUST‐AHF Study
por: Zhang, Jingjing, et al.
Publicado: (2020)

Should all patients receive dual chamber pacing ICDs? The rationale for the DAVID trial
por: Wilkoff, Bruce L
Publicado: (2001)

Design of a prospective patient‐level pooled analysis of two parallel trials of empagliflozin in patients with established heart failure
por: Packer, Milton, et al.
Publicado: (2020)

Mechanisms of Diuretic Resistance Study: design and rationale
por: Cox, Zachary L., et al.
Publicado: (2020)

Rationale and Design of the PRegnancy and Infant DEvelopment (PRIDE) Study
por: van Gelder, Marleen M H J, et al.
Publicado: (2013)

The genomics of heart failure: design and rationale of the HERMES consortium
por: Lumbers, R. Thomas, et al.
Publicado: (2021)

Kyoto Congestive Heart Failure (KCHF) study: rationale and design
por: Yamamoto, Erika, et al.
Publicado: (2017)

Rate or Rhythm Control in CRT (RHYTHMIC): Study rationale and protocol
por: Elliott, Mark K., et al.
Publicado: (2022)

German Cardiac Arrest Registry: rationale and design of G-CAR
por: Pöss, Janine, et al.
Publicado: (2022)

Clinical impact of increasing left ventricular pacing output in cardiac resynchronization therapy – the new optimization strategy
por: Ishibashi, Kohei, et al.
Publicado: (2016)

TranslatiOnal Registry for CardiomyopatHies (TORCH) – rationale and first results
por: Seyler, Claudia, et al.
Publicado: (2017)

Rationale and design of a randomised trial of trientine in patients with hypertrophic cardiomyopathy
por: Farrant, John, et al.
Publicado: (2023)

Earlier Right Ventricular Pacing in Cardiac Resynchronization Therapy for a Patient with Right Axis Deviation
por: Hattori, Yusuke, et al.
Publicado: (2017)

Left univentricular pacing for cardiac resynchronization therapy using rate-adaptive atrioventricular delay
por: Pu, Li-Jin, et al.
Publicado: (2017)

Fluctuation of left ventricular thresholds and required safety margin for left ventricular pacing with cardiac resynchronization therapy
por: Burri, Haran, et al.
Publicado: (2009)

Rationale and design of REDUCE‐IT: Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial
por: Bhatt, Deepak L., et al.
Publicado: (2017)

Heart failure prevalence in the general population: SOBOTA‐HF study rationale and design
por: Lainscak, Mitja, et al.
Publicado: (2019)

Rationale and design of the CardioMEMS Post‐Market Multinational Clinical Study: COAST
por: Cowie, Martin R., et al.
Publicado: (2020)

Regional management of worsening heart failure: rationale and design of the CHAIN‐HF registry
por: Shakoor, Abdul, et al.
Publicado: (2023)

Sacubitril/valsartan for cardioprotection in breast cancer (MAINSTREAM): design and rationale of the randomized trial
por: Tajstra, Mateusz, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_emr3bqpv0u4fb9dkmc2vkk5in3